偏头痛
医学
指南
叙述性评论
梅德林
降钙素基因相关肽
儿科
临床试验
重症监护医学
精神科
内科学
病理
受体
神经肽
政治学
法学
作者
Juliana VanderPluym,M. Cristina Victorio,Christopher Oakley,Reena Gogia Rastogi,Serena L. Orr
出处
期刊:Neurology
[Ovid Technologies (Wolters Kluwer)]
日期:2023-10-31
卷期号:101 (18): 788-797
被引量:2
标识
DOI:10.1212/wnl.0000000000207677
摘要
Migraine is common in children and adolescents and can cause significant disability. There are relatively limited evidence-based treatment options available, especially when compared with treatment of migraine in adults. The Pediatric Research Equity Act requires the study of a new drug or biologic in pediatric populations. As such it is mandatory that the newest migraine treatment options available for adults be evaluated in children and adolescents. It will take years before results from clinical trials in pediatric patients become available. In the meantime, there is eagerness among clinicians to seek out the existing evidence that may help provide clarity on utilization of the newer migraine therapies in children and adolescents because many of the currently available, guideline-recommended treatments do not provide benefit for all patients. In this narrative review, the literature regarding onabotulinumtoxinA, neuromodulatory devices, calcitonin gene-related peptide (CGRP) monoclonal antibodies, 5-hydroxytryptamine (1F) agonists (i.e., ditans), and CGRP small-molecule receptor antagonists (i.e., gepants) for the treatment of migraine in children and adolescents will be summarized.
科研通智能强力驱动
Strongly Powered by AbleSci AI